公开(公告)号：US20140057938A1

公开(公告)日：2014-02-27

申请号：US14068707

申请日：2013-10-31

Applicant: Pfizer Inc.

Inventor： AMY BETH DOUNAY ,  LAURA ANN MCALLISTER ,  VINOD DIPAK PARIKH ,  SUOBAO RONG ,  PATRICK ROBERT VERHOEST

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D487/04

Abstract: Compounds of Formula I: wherein X, Y, Z, R1, R2, R3, R4 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

Abstract translation: 式I化合物：其中X，Y，Z，R 1，R 2，R 3，R 4如本文所定义，及其药学上可接受的盐被描述为可用于治疗与精神分裂症和其他精神病学，神经变性和/ 或哺乳动物包括人类的神经障碍。

公开(公告)号：US20190382359A1

公开(公告)日：2019-12-19

申请号：US16547037

申请日：2019-08-21

Applicant: PFIZER INC.

Inventor： CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  ELIZABETH MARY BECK ,  MICHAEL AARON BRODNEY ,  ADAM MATTHEW GILBERT ,  CHRISTOPHER JOHN HELAL ,  DOUGLAS SCOTT JOHNSON ,  JUSTIN IAN MONTGOMERY ,  STEVEN VICTOR O'NEIL ,  BRUCE NELSEN ROGERS ,  PATRICK ROBERT VERHOEST ,  DAMIEN WEBB

IPC: C07D295/14 ,  C07D493/10 ,  C07D405/12 ,  C07D413/14 ,  C07D405/14 ,  C07F9/6561 ,  C07D515/10 ,  C07D471/08 ,  C07D211/48 ,  C07D487/04 ,  C07D471/10 ,  C07D401/12 ,  C07D491/107 ,  C07D498/10 ,  C07D403/04 ,  C07D401/04 ,  C07D401/14

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20180208608A1

公开(公告)日：2018-07-26

申请号：US15876698

申请日：2018-01-22

Applicant: PFIZER INC.

Inventor： MICHAEL AARON BRODNEY ,  CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  CHRISTOPHER JOHN HELAL ,  STEVEN VICTOR O'NEIL ,  PATRICK ROBERT VERHOEST

IPC: C07D513/10 ,  C07D221/20 ,  A61P35/00 ,  A61P3/00 ,  A61P9/00 ,  A61P25/00

Abstract: The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20180065943A1

公开(公告)日：2018-03-08

申请号：US15808242

申请日：2017-11-09

Applicant: PFIZER INC.

Inventor： CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  ELIZABETH MARY BECK ,  MICHAEL AARON BRODNEY ,  ADAM MATTHEW GILBERT ,  CHRISTOPHER JOHN HELAL ,  DOUGLAS SCOTT JOHNSON ,  JUSTIN IAN MONTGOMERY ,  STEVEN VICTOR O'NEIL ,  BRUCE NELSEN ROGERS ,  PATRICK ROBERT VERHOEST ,  DAMIEN WEBB

IPC: C07D295/14 ,  C07D405/14 ,  C07D413/14 ,  C07D515/10 ,  C07D471/08 ,  C07D211/48 ,  C07D487/04 ,  C07D471/10 ,  C07D401/12 ,  C07D491/107 ,  C07D498/10 ,  C07D403/04 ,  C07D401/04 ,  C07D401/14 ,  C07D493/10 ,  C07D405/12 ,  C07F9/6561

CPC classification number: C07D295/14 ,  C07D211/48 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D493/10 ,  C07D498/10 ,  C07D515/10 ,  C07F9/6561

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20190276472A1

公开(公告)日：2019-09-12

申请号：US16420544

申请日：2019-05-23

Applicant: PFIZER INC.

Inventor： MICHAEL AARON BRODNEY ,  CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  CHRISTOPHER JOHN HELAL ,  STEVEN VICTOR O'NEIL ,  PATRICK ROBERT VERHOEST

IPC: C07D513/10 ,  C07D295/185 ,  C07D491/10 ,  C07D221/20 ,  C07D401/08 ,  C07D401/12

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20180208607A1

公开(公告)日：2018-07-26

申请号：US15874987

申请日：2018-01-19

Applicant: PFIZER INC.

Inventor： MICHAEL AARON BRODNEY ,  CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  CHRISTOPHER JOHN HELAL ,  STEVEN VICTOR O'NEIL ,  PATRICK ROBERT VERHOEST

IPC: C07D513/10 ,  C07D221/20

CPC classification number: C07D513/10 ,  C07D221/20 ,  C07D295/185 ,  C07D401/08 ,  C07D401/12 ,  C07D491/10

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

公开(公告)号：US20170029390A1

公开(公告)日：2017-02-02

申请号：US15221658

申请日：2016-07-28

Applicant: PFIZER INC.

Inventor： CHRISTOPHER RYAN BUTLER ,  LAURA ANN MCALLISTER ,  ELIZABETH MARY BECK ,  MICHAEL AARON BRODNEY ,  ADAM MATTHEW GILBERT ,  CHRISTOPHER JOHN HELAL ,  DOUGLAS SCOTT JOHNSON ,  JUSTIN IAN MONTGOMERY ,  STEVEN VICTOR O'NEIL ,  BRUCE NELSEN ROGERS ,  PATRICK ROBERT VERHOEST ,  DAMIEN WEBB

IPC: C07D295/14 ,  C07D401/04 ,  C07D403/04 ,  C07D498/10 ,  C07D491/107 ,  C07D405/14 ,  C07D471/10 ,  C07D487/04 ,  C07D211/48 ,  C07D471/08 ,  C07D515/10 ,  C07F9/6561 ,  C07D401/14 ,  C07D401/12

CPC classification number: C07D295/14 ,  C07D211/48 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D491/107 ,  C07D493/10 ,  C07D498/10 ,  C07D515/10 ,  C07F9/6561

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Abstract translation: 和其药学上可接受的盐; 制备过程; 中间体用于制备; 含有这些化合物或盐的组合物及其用于治疗MAGL介导的疾病和病症的用途，包括例如疼痛，炎性疾病，创伤性脑损伤，抑郁症，焦虑症，阿尔茨海默病，代谢紊乱，中风或癌症。